Epigenetics Market is Growing at a CAGR of 13.1% by 2027

The global Epigenetics Market is forecasted to grow at a high rate due to an increase in government spending in research & development in genomics, rising demand for genetic therapies, and increasing prevalence of chronic diseases such as cancer. The Global Epigenetics Market was valued at USD 1.3 Bn in 2020 and is expected to reach USD 3.3 Bn by 2027, with a growing CAGR of 13.1 % during the forecast period.

Epigenetics is defined as the study of genes and their behavior with respect to the body. Epigenetics led to the changes in the phenotype of an organism, wherein DNA or RNA sequence remains constant. Epigenetic changes include changes in gene expression and activities. For instance, epigenetics alters the structure of DNA such as DNA methylation.

The driving factors influencing the growth of the global epigenetics market include a rise in demand for protein expression systems, an increase in usage of antibodies specific detection procedures, and the extensive presence of pipeline products. Moreover, technological advances in the epigenetics industry in the detection of methylation markers such as Epi Prolung BL reflex assay by epigenomics in cancer diagnosis by determining SHOX2 is expected to fuel the growth of the global epigenetics market. The rise in demand for personalized medicines and increase in R&D infrastructure thrives the growth of the global epigenetics industry.

Researchers at UC San Francisco and Whitehead Institute developed and described novel CRISPR-based tool called “CRISPoff” that allows scientists to cut down off almost any gene in human cells without editing a single genetic code. Researchers proved that once the gene is switched off, it is expected to remain inert in the cell for hundreds of generations unless it is switched back on with CRISPRon.

Since epigenome plays a crucial role in disease management such as cancer and it is believed that CRISPRoff technology may lead to powerful epigenetic therapies. Such inventions and research are expected to leverage the growth of the epigenetics market during the forecast period.

Global Epigenetic Market by Region Outlook (Revenue, USD Million, 2021-2027)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Based on region, North America held the maximum market share in 2020 about 35% due to high prevalence of chronic diseases like cancer and huge investment in research activities for the development of epigenetic products. Moreover, growing collaborations between pharmaceutical companies for the development of improved epigenetic therapeutics in this region drives the demand for epigenetics market.

On the contrary, Asia-Pacific is anticipated to observe highest market growth during forecast period due to increase in diversification in healthcare market, growing prevalence of infectious diseases, and growing R&D facilities boost the growth of epigenetics market in this region. Moreover, low-labour cost and rising CRO’s & pharmaceutical industry thrives the growth of market players in this region.

The Global Epigenetics Market Segmentation:

Global Epigenetics Market by Product Type Outlook (Revenue, USD Million, 2021-2027)

  • Kits
  • Enzymes
  • Reagents
  • Instruments

Global Epigenetics Market by Application Type Outlook (Revenue, USD Million, 2021-2027)

  • Oncology
  • Developmental Biology
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Immunology
  • Others

Global Epigenetics Market by Technology Type Outlook (Revenue, USD Million, 2021-2027)

  • Methylation
  • Phosphorylation
  • Acetylation
  • Others

Key Findings:

  • Based on product, kits product segment accounted for highest market share in 2020 and expected to increase more during forecast period
  • Based on application, oncology segment dominated epigenetic market in 2020 and expected to maintain the same dominance during forecast period due to increase in number of cancer patients
  • Based on technology, Methylation held largest market share in 2020 and expected to expand more during forecast period
  • Based on region, North America held the maximum market share in 2020 due to local presence of major market players, recent product approvals, and high adoption in the region

Company Profiles and Competitive Intelligence

The key players operating in the epigenetics market are:

  • Illumina
  • Thermo Fisher          
  • Diagenode
  • Merck Millipore
  • Abcam
  • Active Motif
  • New England Biolabs
  • Agilent
  • Zymo Research
  • PerkinElmer
  • Bio-Rad
  • Novartis International AG
  • Sigma-Aldrich Corporation
  • Eisai Co. Ltd
  • CellCentric Ltd
  • Chroma Therapeutics Ltd
  • Syndax Pharmaceuticals
  • Oncolys Biopharma Inc.
  • Valirx Plc

Recent News:

  • In March 2021, Craith Lab recalled the direct-to-consumer model of selling products for its epigenetic skin care brand and opted to distribute products via beauticians and salon network to avoid its misuse and provide guidance of its effect.
  • In February 2020, Twist Bioscience Corporation launched new NGS solution that include 99% of protein coding genes and Twist Targeted Methylation Sequencing Solution used to study methylation pattern change in cancer.
  • In August 2018, 10X Genomics acquired Epinomics start-up to expand their portfolio and add its technology in single-cell sequencing product.


Quick Inquiry

Follow Us